Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results

Telomir Pharmaceuticals (NASDAQ:TELO) announced its quarterly earnings data on Friday. The company reported ($0.01) earnings per share (EPS) for the quarter, FiscalAI reports.

Telomir Pharmaceuticals Price Performance

Shares of NASDAQ TELO traded down $0.07 during midday trading on Friday, hitting $0.71. The stock had a trading volume of 152,608 shares, compared to its average volume of 117,874. The firm has a market cap of $52.32 million, a P/E ratio of -0.78 and a beta of -0.19. Telomir Pharmaceuticals has a fifty-two week low of $0.69 and a fifty-two week high of $1.58. The company’s 50-day simple moving average is $1.10 and its 200 day simple moving average is $1.21.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Telomir Pharmaceuticals during the 2nd quarter worth about $359,000. Bank of New York Mellon Corp acquired a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $66,000. Finally, OneDigital Investment Advisors LLC acquired a new stake in shares of Telomir Pharmaceuticals during the 2nd quarter worth approximately $29,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on TELO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Thursday, October 15th. Maxim Group began coverage on Telomir Pharmaceuticals in a report on Thursday, September 17th. They issued a “buy” rating and a $4.00 target price for the company. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.00.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc is a development-stage biotechnology company focused on therapies intended to address age-related diseases and conditions. The company’s research is centered on telomere biology, a field involving the protective DNA sequences at the ends of chromosomes that are associated with cellular aging.

Telomir’s lead investigational product is TELOMIR-1, an orally administered small-molecule compound being developed to promote telomere lengthening and support cellular health.